# A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

> **NCT06282991** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 73 (actual)

## Conditions studied

- Non-Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT06282991
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-22
- **Primary completion:** 2021-01-18
- **Final completion:** 2021-01-18
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06282991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06282991, "A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06282991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*